CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) announced today that it is awarding $2 million to Portuguese biotechnology company Immunethep to develop a vaccine against invasive serotypes of Escherichia coli.
The company will use the money to advance its work on a conjugate peptide-based vaccine that can induce immunity to E coli, which can cause serious and life-threatening infections of the bloodstream, urinary tract, and other organs. The vaccine being developed by Immunethep has demonstrated efficacy against E coli and four other bacterial pathogens—Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, and Streptococcus agalactiae—in animal models.
Invasive E coli infections are a particular concern for vulnerable populations such as the elderly, people with compromised immune systems, and those with chronic health conditions, and the rising prevalence of antimicrobial resistance is making them harder to treat. No current E coli vaccine exists, and drugmakers Sanofi and Johnson & Johnson recently halted a phase 3 study on their E coli vaccine candidate after a data review showed it was ineffective.
Potential solution for increasingly resistant infections
"This technology leverages a novel platform to induce robust, long-lasting immunity against E. coli and other dangerous pathogens, which could have broad implications for preventing serious infections in vulnerable populations," Erin Duffy, PhD, CARB-X's chief of research and development, said in a press release. "By supporting the development of this vaccine, we are advancing a potential solution that could help combat infections that are increasingly difficult to treat with antibiotics.”
Since its founding in 2016, CARB-X has supported 113 early-stage projects designed to prevent, treat, and diagnose antibiotic-resistant infections. Of those projects, 19 have advanced into or completed clinical trials, 12 remain active in clinical development, and two products have reached the market.